# EDGAR Filing Document

**Accession Number:** 0001946573
**File Stem:** 0000000000-25-007243
**Filing Date:** 2025-7
**Character Count:** 6550
**Document Hash:** 51f2b44e6d6cea87e0a83f69fc7d7e3c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-007243.hdr.sgml**: 20251217

**ACCESSION NUMBER**: 0000000000-25-007243

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250709

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Kindly MD, Inc.
- **CENTRAL INDEX KEY:** 0001946573
- **STANDARD INDUSTRIAL CLASSIFICATION:** FINANCE SERVICES [6199]
- **ORGANIZATION NAME:** 09 Crypto Assets
- **EIN:** 843829824
- **STATE OF INCORPORATION:** UT
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 001-42103

**BUSINESS ADDRESS:**
- **STREET 1:** 5097 SOUTH 900 EAST
- **STREET 2:** SUITE 100
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84117
- **BUSINESS PHONE:** (385) 388-8220

**MAIL ADDRESS:**
- **STREET 1:** 5097 SOUTH 900 EAST
- **STREET 2:** SUITE 100
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84117
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001213900-25-056334

## Text-Extract

```

                                                           July 9, 2025

Tim Pickett
Chief Executive Officer and Chairman of the Board
Kindly MD, Inc.
5097 South 900 East Suite 100
Salt Lake City, UT 84117

       Re: Kindly MD, Inc.
           Information Statement on Schedule 14C
           Filed June 23, 2025
           File No. 001-42103
Dear Tim Pickett:

       We have reviewed your filing and have the following comments.

       Please respond to this letter within ten business days by providing the
requested
information or advise us as soon as possible when you will respond. If you do
not believe a
comment applies to your facts and circumstances, please tell us why in your
response.

       After reviewing your response to this letter, we may have additional
comments.

Information Statement on Schedule 14C filed June 23, 2025
Cover Page

1.     We note your disclosure that you obtained approval of holders of
approximately
       50.76% of the outstanding voting power of the Company on May 18, 2025
and
       approximately 50.14% of the outstanding voting power of the Company on
June 19,
       2025 by written consents. However, the beneficial ownership table
included on page
       108 of the information statements shows that the directors and executive
officers of
       the Company only held approximately 40.79% of the outstanding voting
power of the
       Company as of June 1, 2025 and does not identify any shareholders
holding more than
       5% of the outstanding shares that are not already included in the 40.79%
total.
       Additionally, we note your disclosure in the Background of the Merger
section
       regarding the Shareholder Support Agreement and Lock-Up Agreement to be
signed
       by a majority of the Company's shareholders and your statement that
"[o]n April 18,
       2025, KindlyMD followed up with updated drafts of certain ancillary
documents,
       including note to the Shareholder Support Agreement and Lock-Up
Agreement
       indicating which KindlyMD shareholders had agreed to be party to such
       agreements." In your response letter, please identify the shareholders
who provided
 July 9, 2025
Page 2

       written consent for these actions, including each consenting stockholder
  s respective
       share ownership and relationship to the Company. Please also describe
the events that
       led to your receipt of the written consents and provide an analysis of
whether the
       process of obtaining the consents involved a solicitation within the
meaning of
       Exchange Act Rule 14a- 1(l).
Information about Nakamoto, page 38

2.     Please expand your disclosure regarding your plan of operation for the
next twelve
       months by describing the source of capital for your acquisition of
bitcoin and any
       acquisition of, or investment in, companies that have bitcoin
treasuries. Please
       specify the amount of bitcoin currently held by Kindly MD or Nakamoto
and the
       amount of bitcoin you intend to purchase with the proceeds from the PIPE
Financing,
       the Additional Subscription Agreements, the Debt Financing, and the
Promissory
       Note with BTC so that investors understand the estimated size of the
bitcoin treasury
       of the Combined Company and your business strategy related to the
acquisition of, or
       investment in, companies that have bitcoin treasuries.
3.     Please describe how you intend to generate bitcoin yield.
4.     Please disclose an estimated timeline of the building of your bitcoin
treasury for the
       next twelve months, the implementation of your plans to generate bitcoin
yield, the
       acquisition and operation of companies in various industries that have
bitcoin
       treasuries and any planned investments in companies with bitcoin
treasuries. Include
       an estimate of the cost of each step, the sources of capital of each
step and the
       challenges you may face, including the payment of your debt obligations.
Adjustments to Unaudited Pro Forma Condensed Combined Statements of Operations,
page
F-7

5.     We note you recorded pro forma adjustment (BB) and (DD) related to the
change in
       fair value of the company   s Bitcoin investment for the pro forma
periods. Please
       provide us your analysis as to how the fair value adjustments comply
with Article 11
       pro forma guidance under Regulation S-X. In that regard, Item
11-02(a)(6)(i)(A) and
       (B) indicate that for a probable transaction pro forma adjustments
should be calculated
       using the most recent practicable date prior to the effective date,
qualification date or
       the mail date. As such, it is unclear why any change in fair value of
intangible assets
       would be recorded in your unaudited pro forma condensed combined
statements of
       operations.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence
of action by the staff.

       Please contact Conlon Danberg at 202-551-4466 or Lauren Nguyen at
202-551-3642
with any other questions.

                                                             Sincerely,
 July 9, 2025
Page 3

                              Division of Corporation Finance
                              Office of Industrial Applications and
                              Services
cc:   Callie T. Jones, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._